International Clinical Pathology Journal

2019 ◽  
Keyword(s):  
Clinical Pathology

On Future Directions in Pathology

1982 ◽  
Vol 40 ◽  
pp. 274-277
Author(s):  
Benjamin F. Trump ◽  
Irene K. Berezesky ◽  
Raymond T. Jones
Keyword(s):  
Electron Microscopy ◽  
Transmission Electron Microscopy ◽  
Clinical Pathology ◽  
Future Directions ◽  
Diagnostic Pathology ◽  
The Past ◽  
Transmission Electron ◽  
Organ Systems ◽  
The Many

The role of electron microscopy and associated techniques is assured in diagnostic pathology. At the present time, most of the progress has been made on tissues examined by transmission electron microscopy (TEM) and correlated with light microscopy (LM) and by cytochemistry using both plastic and paraffin-embedded materials. As mentioned elsewhere in this symposium, this has revolutionized many fields of pathology including diagnostic, anatomic and clinical pathology. It began with the kidney; however, it has now been extended to most other organ systems and to tumor diagnosis in general. The results of the past few years tend to indicate the future directions and needs of this expanding field. Now, in addition to routine EM, pathologists have access to the many newly developed methods and instruments mentioned below which should aid considerably not only in diagnostic pathology but in investigative pathology as well.

The Adaptation of Medical Records to Epidemiological Use

1965 ◽  
Vol 04 (03) ◽  
pp. 136-140
Author(s):  
Cl Jeanty
Keyword(s):  
Medical Records ◽  
Clinical Pathology ◽  
Time Variable ◽  
Special Care ◽  
General Description ◽  
Causal Relations ◽  
Laboratory Techniques ◽  
Original Record ◽  
Statistical Studies

A method is described in an attempt to make medical records suitable for epidemiologigri: purposes. Every case of a disease is recorded on an appropriate punched card with the object of working towards a general description of a disease through the collation of several cases of the same diagnosis. This punched card represents a very great condensation of the original record. Special care has been applied to state as precisely as possible the time variable, particularly as far as its origin and unit of measure are concerned, in order to demonstrate the existence of causal relations between diseases. Such cards are also intended to make easier statistical studies in clinical pathology, in evaluation of new laboratory techniques, and in therapeutical trials.

scholarly journals Mucosal Challenge Ferret Models of Ebola Virus Disease

Pathogens ◽  
2021 ◽  
Vol 10 (3) ◽  
pp. 292
Author(s):  
Trevor Brasel ◽  
Jason E. Comer ◽  
Shane Massey ◽  
Jeanon Smith ◽  
Jennifer Smith ◽  
...  
Keyword(s):  
Disease Progression ◽  
Intranasal Administration ◽  
Ebola Virus ◽  
Advanced Disease ◽  
Virus Disease ◽  
Small Animal ◽  
Clinical Pathology ◽  
Small Animal Model ◽  
Post Challenge ◽  
Mustela Putorius

Recent studies have shown the domestic ferret (Mustela putorius furo) to be a promising small animal model for the study of Ebola virus (EBOV) disease and medical countermeasure evaluation. To date, most studies have focused on traditional challenge routes, predominantly intramuscular and intranasal administration. Here, we present results from a non-clinical pathogenicity study examining oronasal, oral, and ocular mucosal challenge routes in ferrets. Animals were challenged with 1, 10, or 100 plaque forming units EBOV followed by monitoring of disease progression and biosampling. Ferrets administered virus via oronasal and oral routes met euthanasia criteria due to advanced disease 5–10 days post-challenge. Conversely, all ferrets dosed via the ocular route survived until the scheduled study termination 28-day post-challenge. In animals that succumbed to disease, a dose/route response was not observed; increases in disease severity, febrile responses, serum and tissue viral load, alterations in clinical pathology, and gross/histopathology findings were similar between subjects. Disease progression in ferrets challenged via ocular administration was unremarkable throughout the study period. Results from this study further support the ferret as a model for EBOV disease following oral and nasal mucosa exposure.

scholarly journals Long-term safety evaluation of Daxocox® tablets (enflicoxib) in dogs after weekly oral administrations for seven months

2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Josep Homedes ◽  
Marta Salichs ◽  
Antonio Guzman
Keyword(s):  
Safety Margin ◽  
Clinical Signs ◽  
Safety Evaluation ◽  
Clinical Pathology ◽  
Occult Blood ◽  
Study Groups ◽  
Placebo Control ◽  
Relevant Dose ◽  
Mucosal Bleeding ◽  
Animal Safety

Abstract Background Daxocox® [Ecuphar/Animalcare Group] contains the selective COX-2 inhibitor enflicoxib, approved in the EU for the treatment of pain and inflammation associated with osteoarthritis in dogs. The safety of Daxocox® was evaluated in a target animal safety study: Groups of 4 dogs per sex each were treated once weekly with placebo or Daxocox tablets at 1-, 3- and 5-times (1X, 3X and 5X) the maximum recommended therapeutic dose of enflicoxib (0, 4, 12 or 20 mg/kg, respectively). After an initial loading dose, dogs in the placebo control, 1X and 3X groups were administered for 32 weeks, and those in the 5X group were administered for 13 weeks. Dogs were subjected to daily food consumption measurements and clinical and dose observations. Body weight measurements, physical examinations, clinical pathology, urinalysis, faecal occult blood (FOB) and electrocardiographic (ECG) and blood pressure measurements, buccal mucosal bleeding time (BMBT), ophthalmology and gastroduodenal endoscopy examinations were conducted throughout the study. At study completion, all dogs were subjected to gross necropsy. Histopathology was performed on selected tissues from all animals in all groups. Results No clinical signs were noted, and no toxicologically relevant dose-associated effects were observed. Conclusions Results show that Daxocox® is well-tolerated and has a broad safety margin when administered as directed in dogs.

Sign in / Sign up

Export Citation Format

Share Document